NLRP3 and chronic obstructive pulmonary disease: Evidence indicates that MCC950 enhances survival rates in SARS-CoV-2–infected mice, reduces tissue inflammation, suppresses NLRP3 inflammasome activation induced by influenza A virus (IAV) in human bronchial epithelial cells, and improves outcomes in rat models of chronic obstructive pulmonary disease (COPD) [119,120,121].